LAMATTINA JOHN L

The insider at CIK 0001216074 — a Pfizer Inc. (PFE) executive whose register spans 268 transactions — is executing a measured, multi-quarter unwind of a substantial Ligand Pharmaceuticals (LGND) position acquired through years of RSU vesting, with the most recent filing showing four separate sell transactions on June 10, 2026 totaling approximately 4,391 shares at$247–$252 per share — a price near LGND's recent trading range and approximately 10–12x the option or RSU grant strike prices embedded in the insider's historical cost basis. The sell sequence on June 10 is the latest chapter in a deliberate distribution program: the insider sold 2,161 shares in March 2026 at $200.76 while simultaneously acquiring 2,161 shares at the$114.15 grant strike — a partial exercise-and-cover cycle — and then sold the exercised shares in June 2026 at$247–$252 after LGND's stock appreciated roughly 30% from March to June. The pattern is consistent with a tax-managed distribution strategy: exercise options at the grant price, hold or immediately sell the acquired shares depending on diversification needs and tax-bracket management. The register contains no LGND acquisitions in the recent window, only sells — the accumulation phase ended and the distribution phase has been ongoing across multiple quarters. Pfizer itself has no recent transactions in the file, suggesting the insider's Pfizer holdings are either below reporting thresholds or fully diversified away. The honest read: an insider is methodically distributing a long-vested LGND position through a series of well-timed option exercises and partial sales, extracting value at rising prices — a signal of personal financial management rather than a view on LGND's prospects.